<SEC-DOCUMENT>0001193125-26-123543.txt : 20260325
<SEC-HEADER>0001193125-26-123543.hdr.sgml : 20260325
<ACCEPTANCE-DATETIME>20260325133152
ACCESSION NUMBER:		0001193125-26-123543
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260325
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260325
DATE AS OF CHANGE:		20260325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CORCEPT THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001088856
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				770487658
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50679
		FILM NUMBER:		26790917

	BUSINESS ADDRESS:	
		STREET 1:		101 REDWOOD SHORES PARKWAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		650.688.8803

	MAIL ADDRESS:	
		STREET 1:		101 REDWOOD SHORES PARKWAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d123475d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cort="http://www.corcept.com/20260325" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2026-03-25_to_2026-03-25">CORCEPT THERAPEUTICS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-234">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-03-25_to_2026-03-25">0001088856</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="cort-20260325.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-03-25_to_2026-03-25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001088856</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-03-25</xbrli:startDate> <xbrli:endDate>2026-03-25</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-245">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt:datemonthdayyearen" id="ixv-246">March&#160;25, 2026</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (date of earliest event reported)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Corcept Therapeutics Incorporated</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:stateprovnameen" id="ixv-247">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-248">000-50679</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-249">77-0487658</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-250">101 Redwood Shores Parkway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-251">Redwood City</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-252">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-253">94065</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-254">(650)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-255">327-3270</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:boolballotbox" id="ixv-256">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:boolballotbox" id="ixv-257">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:boolballotbox" id="ixv-258">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:boolballotbox" id="ixv-259">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-260">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-261">CORT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:exchnameen" id="ixv-262">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-03-25_to_2026-03-25" format="ixt-sec:boolballotbox" id="ixv-263">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;25, 2026, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved Lifyorli<sup style="font-size:75%; vertical-align:top">&#8482;</sup> (relacorilant) in combination with <span style="white-space:nowrap">nab-paclitaxel</span> for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01. Financial Statements and Exhibits </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:89%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibits&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d123475dex991.htm">Press Release of Corcept Therapeutics Incorporated, March&#160;25, 2026. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">CORCEPT THERAPEUTICS INCORPORATED</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;25, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Atabak Mokari</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: Atabak Mokari</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: &#8194;Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d123475dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="6">


<IMG SRC="g123475g0324082552942.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>CONTACT:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Investor inquiries:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>ir@corcept.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Media inquiries:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>communications@corcept.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">www.corcept.com</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FDA Approves Corcept&#8217;s Selective Glucocorticoid Receptor Antagonist Lifyorli<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (relacorilant) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plus <FONT STYLE="white-space:nowrap">Nab-Paclitaxel</FONT>
for Treatment of Patients with Platinum-Resistant Ovarian Cancer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redwood City, Calif.,</B> (March 25, 2026) &#8212; Corcept Therapeutics
Incorporated&nbsp;(NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol,
today announced that the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) has approved Lifyorli<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (relacorilant) in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> for
the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Lifyorli is the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> selective glucocorticoid receptor antagonist (SGRA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval was based on the positive outcomes of
Lifyorli&#8217;s pivotal ROSELLA trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, at least one of which included bevacizumab.&nbsp;Patients were randomized 1:1 to receive
either Lifyorli plus <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> or <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> monotherapy. No biomarker selection was required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROSELLA met its dual primary endpoints of progression-free and overall survival. Patients treated with Lifyorli in addition to
<FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> experienced a 35&nbsp;percent reduction in the risk of death compared to patients treated with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> alone (hazard ratio: 0.65; <FONT
STYLE="white-space:nowrap">p-value:</FONT> 0.0004), with a median overall survival (OS) of 16.0 months, compared to 11.9 months for patients receiving <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> alone, a difference of 4.1 months. Patients
who received Lifyorli in addition to <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> also experienced a 30&nbsp;percent reduction in the risk of disease progression (hazard ratio: 0.70; <FONT STYLE="white-space:nowrap">p-value:</FONT> 0.008),
as assessed by blinded independent central review <FONT STYLE="white-space:nowrap">(PFS-BICR),</FONT> compared to patients treated with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination of Lifyorli with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> was well-tolerated and manageable. The safety of Lifyorli was assessed
in a pooled analysis of patients from ROSELLA and Lifyorli&#8217;s Phase 2 trial. The prescribing information for Lifyorli includes warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions
treated with glucocorticoids and embryo-fetal toxicity. The most common adverse reactions experienced by more than 20&nbsp;percent of patients (including laboratory abnormalities) were decreased hemoglobin, decreased neutrophils, fatigue, nausea,
diarrhea, decreased platelets, rash and decreased appetite. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from ROSELLA were first presented at ASCO 2025 (American Society of Clinical Oncology) with
simultaneous publication in&nbsp;<U>The Lancet</U>. Complete results from ROSELLA will be presented at the Society of Gynecologic Oncology (SGO) meeting in April. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Data demonstrate that Lifyorli plus <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> provides a clinically meaningful benefit in overall survival
for patients with platinum-resistant ovarian cancer and is well tolerated. Lifyorli is positioned to become a new <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> treatment,&#8221; said&nbsp;Rob
Coleman, M.D., Texas Oncology and special advisor to the president of the GOG Foundation. &#8220;Having a new treatment for this advanced, recurrent disease will provide clinicians with a compelling option to help patients with this extremely <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancer.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;The FDA&#8217;s approval of Lifyorli
in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> is welcome news to all of us in the ovarian cancer community,&#8221; said Sarah DeFeo, Chief Program Officer at Ovarian Cancer Research Alliance (OCRA). &#8220;We are
grateful to everyone who participated in the clinical trials, their families and the physicians who helped advance this urgently needed treatment option for patients with platinum-resistant ovarian cancer.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;It is a privilege to bring forward a new treatment for patients who historically have had few options,&#8221; said Joseph Belanoff, M.D.,
Corcept&#8217;s Chief Executive Officer. &#8220;We have worked for years to demonstrate the potential of cortisol modulation in oncology. Today&#8217;s approval of Lifyorli is an important first step, but there is much more to explore with this new
mode of treatment. We extend our deep appreciation to&nbsp;the patients&nbsp;and healthcare providers&nbsp;who participated in the clinical trials&nbsp;that made&nbsp;this approval possible.&#8221;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROSELLA enrolled patients with <FONT STYLE="white-space:nowrap">platinum-resistant</FONT> ovarian cancer at sites in the United States, Europe, South Korea,
Brazil, Argentina, Canada and Australia, and was conducted in collaboration with The GOG Foundation, Inc. <FONT STYLE="white-space:nowrap">(GOG-F),</FONT> the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific
Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology Group (LACOG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ovarian Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ovarian cancer is the fifth most
common cause of cancer death in women. Patients whose disease returns less than six months after receiving platinum-containing therapy have &#8220;platinum-resistant&#8221; disease. There are few treatment options for these women. Approximately
20,000 women with platinum-resistant disease are candidates to start a new therapy each year in&nbsp;the United States, with at least an equal number in&nbsp;Europe. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cortisol&#8217;s Role in Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cortisol plays a role in tumor growth through several mechanisms. It helps solid tumors resist chemotherapy by inhibiting cellular apoptosis &#8212; the
tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenic signaling in the cells to which it binds. Cortisol also suppresses the body&#8217;s immune response, which weakens its
ability to fight all diseases, including cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corcept is developing relacorilant in ovarian, endometrial, cervical, pancreatic and prostate cancers.
Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. It has been designated an orphan drug by the European Commission&nbsp;(EC) for the treatment of ovarian cancer. Corcept has submitted
a Marketing Authorisation Application (MAA) to the&nbsp;European Medicines Agency&nbsp;(EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lifyorli<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lifyorli (relacorilant), approved in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel,</FONT> is the first U.S. Food and Drug
Administration&nbsp;(FDA)-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Lifyorli is an oral medication taken the day before, the day of and the day after treatment with <FONT
STYLE="white-space:nowrap">nab-paclitaxel.</FONT> There is no biomarker requirement for Lifyorli. Lifyorli competitively binds to the glucocorticoid receptor (GR), where it enhances chemotherapy sensitivity by inhibiting cortisol&#8217;s suppression
of apoptosis &#8211; the programmed cell death that chemotherapies such as <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> are meant to cause. Lifyorli does not have any effect at the body&#8217;s other steroid receptors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corcept is committed to timely patient access for Lifyorli. For questions regarding product availability, please contact Lifyorli Support<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-85-LIFYORLI</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(1-855-439-6754).</FONT></FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LIFYORLI
Indication&nbsp;&amp; Usage </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LIFYORLI is indicated in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> for the treatment of
adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received <FONT STYLE="white-space:nowrap">1-3</FONT> prior systemic treatment regimens, at least one of which included bevacizumab. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMPORTANT SAFETY INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contraindications:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ
transplantation) because LIFYORLI antagonizes the effect of glucocorticoids. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warnings and Precautions: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neutropenia and Severe Infections </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LIFYORLI in combination
with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> can cause neutropenia, including febrile neutropenia and severe infections. There was one fatal event of septic shock with febrile neutropenia. Thirty-eight percent of patients initiated
granulocyte colony-stimulating factor<B> </B><FONT STYLE="white-space:nowrap">(G-CSF)</FONT> during the first or second cycle of therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monitor
complete blood counts prior to each weekly treatment with LIFYORLI in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> and as clinically indicated. Based on the severity of neutropenia, delay dose, reduce dose or permanently
discontinue LIFYORLI in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel.</FONT> Consider short-acting <FONT STYLE="white-space:nowrap">G-CSF</FONT> administration as applicable. Consider the possibility of concurrent adrenal
insufficiency, particularly in the setting of serious infection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adrenal Insufficiency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LIFYORLI<B> </B>is a reversible glucocorticoid receptor antagonist and can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during
treatment with LIFYORLI. The risk of adrenal insufficiency is increased in situations of stress, such as acute illness, infection, or surgery. Consider whether supplemental glucocorticoids are required in the perioperative period in patients who
have received LIFYORLI within 30 days of surgery. Monitor patients receiving LIFYORLI for signs and symptoms of adrenal insufficiency. Withhold LIFYORLI and administer glucocorticoid therapy if adrenal insufficiency is suspected. High doses of
supplemental glucocorticoids may be needed to overcome the glucocorticoid receptor antagonism produced by LIFYORLI. After resolution of adrenal insufficiency, resume&nbsp;previous&nbsp;dose, reduce&nbsp;dose&nbsp;or permanently discontinue LIFYORLI
based on severity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exacerbation of Conditions Treated with Glucocorticoids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use of LIFYORLI in patients taking systemic glucocorticoids for other conditions (e.g.,&nbsp;autoimmune disorders) may exacerbate these conditions. LIFYORLI is
a glucocorticoid receptor antagonist that may make systemic glucocorticoids less effective. Similarly, coadministration of systemic glucocorticoids may make LIFYORLI less effective. Monitor patients for reduced effectiveness of LIFYORLI and
glucocorticoids in patients receiving both. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Embryo-Fetal Toxicity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LIFYORLI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status of females
of reproductive potential prior to initiating LIFYORLI treatment. Advise females of reproductive potential, including male patients with female partners of reproductive potential, to use effective contraception during treatment with LIFYORLI and for
1 week after the last dose. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adverse Reactions: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serious adverse reactions occurred in 35% of patients who received LIFYORLI in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel.</FONT> Serious
adverse reactions (&#8805;2%) in patients were neutropenia (4%), pneumonia (3.2%), pleural effusion (3.2%), febrile neutropenia (2.1%), and fatigue (2.1%). Fatal adverse reactions (2.1%) in patients were septic shock (0.5%), cardiac arrest (0.5%),
ischemic stroke (0.5%), and intestinal perforation (0.5%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Permanent discontinuation of LIFYORLI in combination with
<FONT STYLE="white-space:nowrap">nab-paclitaxel&nbsp;due</FONT> to adverse reactions occurred in 9% of patients. The adverse reaction (&gt;2%) that resulted in permanent discontinuation of LIFYORLI in patients was intestinal obstruction (2.6%).
Dosage interruptions of LIFYORLI due to an adverse reaction occurred in 72% of patients. Adverse reactions (&#8805;5%) that required dosage interruptions of LIFYORLI in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> in
patients included neutropenia (44%), anemia (12%), and fatigue (7%). Adverse reactions requiring dose reductions of LIFYORLI included fatigue (1.6%), decreased appetite (1.2%), abdominal pain (0.5%), neutropenia (0.5%), edema (0.5%), and sciatica
(0.5%). LIFYORLI should be interrupted or discontinued when <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> is interrupted or discontinued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
most common adverse reactions (&gt;20%) of patients treated with LIFYORLI plus <FONT STYLE="white-space:nowrap">nab-paclitaxel,</FONT> including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea,
decreased platelets, rash, and decreased appetite. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Drug Interactions: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strong CYP3A Inducers</B><B><I>: </I></B>Avoid coadministration of LIFYORLI plus <FONT
STYLE="white-space:nowrap">nab-paclitaxel</FONT> with strong CYP3A inducers. Both relacorilant and paclitaxel are CYP3A substrates. Coadministration of strong CYP3A inducers can decrease concentrations of relacorilant and paclitaxel, which may
reduce their effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CYP2C8 and Moderate CYP3A Inducers: </B>Monitor for reduced effectiveness of LIFYORLI plus <FONT
STYLE="white-space:nowrap">nab-paclitaxel</FONT> with CYP2C8 inducers and moderate CYP3A inducers. Paclitaxel is a substrate of CYP2C8 and CYP3A, and relacorilant is a CYP3A substrate. Coadministration of CYP2C8 and moderate CYP3A inducers can
decrease concentrations of paclitaxel and relacorilant, which may reduce their effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CYP2C8 Inhibitors: </B>Monitor for increased adverse reactions and modify the dosage for adverse reactions as
recommended.<B> </B>Paclitaxel is a substrate of CYP2C8. Coadministration of CYP2C8 inhibitors may increase concentrations of paclitaxel, which may increase the risk of adverse reactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CYP3A Substrates: </B>Avoid concomitant use unless otherwise recommended in the Prescribing Information for
CYP3A substrates. Relacorilant is a strong CYP3A inhibitor. Relacorilant increases exposure of CYP3A substrates which may increase the risk for adverse reactions related to these substrates. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Certain CYP2C8 Substrates: </B>Avoid concomitant use unless otherwise recommended in the Prescribing
Information for CYP2C8 substrates where minimal concentration changes may lead to reduced effectiveness. Relacorilant is a weak CYP2C8 inducer. Relacorilant decreases exposure of CYP2C8 substrates which may decrease the effectiveness related to
these substrates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use in Specific Populations: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lactation: Advise women not to breastfeed during treatment with LIFYORLI and for 1 week after the last dose.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Geriatric Use: A higher incidence of grade <FONT STYLE="white-space:nowrap">3-4</FONT> adverse events and dosage
modification occurred in patients aged &#8805;65 years compared to younger adult patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hepatic Impairment: Avoid LIFYORLI in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> in
patients with moderate or severe hepatic impairment (total bilirubin &gt;1.5 to 10x ULN and any AST). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Please see the full
<U>Prescribing Information</U> for additional Important Safety Information. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Corcept Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered
more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with Cushing&#8217;s syndrome, solid tumors, ALS and liver disease. In 2012, the company
introduced Korlym<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, the first medication approved by the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) for the treatment of patients with endogenous Cushing&#8217;s syndrome, and in 2026,
the company introduced Lifyorli<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, approved in combination with <FONT STYLE="white-space:nowrap">nab-paclitaxel,</FONT> the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> selective
glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Corcept is headquartered in&nbsp;Redwood City, California. For more information, visit&nbsp;<U>Corcept.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press
release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results
expressed or implied by such forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this press release, forward-looking statements include statements concerning:
Lifyorli&#8217;s efficacy, safety profile and other clinical attributes and its potential to become a new <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> treatment for patients with platinum-resistant
ovarian cancer and provide clinicians with a compelling option to help patients with this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancer; presentation of the ROSELLA trial&#8217;s complete
results at the SGO meeting; our ability to demonstrate the potential of cortisol modulation in oncology and to further explore this mode of treatment; our further development of relacorilant in ovarian, endometrial, cervical, pancreatic and prostate
cancers; the incidence of platinum-resistant ovarian cancer patients expected to start a new therapy each year in the United States and Europe; and our commitment to timely patient access for Lifyorli. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A further description of risks and uncertainties can be found in our SEC filings, which are available at our
website and the SEC&#8217;s website. These risks and uncertainties include, but are not limited to, those related to: our ability to operate our business; our efforts to study and develop Korlym, relacorilant, miricorilant, dazucorilant,
nenocorilant and our other product candidates; those molecules&#8217; clinical attributes; regulatory approvals, mandates, oversight and other requirements imposed on our products or our business by laws, regulations or discretion of government
authorities; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cort-20260325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2605 Build:20260303.5 -->
<!-- Creation date: 3/25/2026 9:28:10 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:cort="http://www.corcept.com/20260325"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.corcept.com/20260325"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cort-20260325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cort-20260325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cort-20260325_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2605 Build:20260303.5 -->
<!-- Creation date: 3/25/2026 9:28:10 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cort-20260325_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2605 Build:20260303.5 -->
<!-- Creation date: 3/25/2026 9:28:10 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cort-20260325.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g123475g0324082552942.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g123475g0324082552942.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !< .,# 2(  A$! Q$!_\0
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MR^)+#QY\>Y+>\GM)?M&B^ ;-]^E:0?X7F[7-P.[M\H.=HZ&OII45%"J J@8
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MX6M_$'A358M4TZ7Y6V'$D+]XY$/*..A!KI[:UAL[>.W@B2&"-0B11J%55'0
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MM)H ^T**_(_7_$?[=?PX^'?_  MW5]6,FC11"]NM)E6)G@@/.YX0-P4#J,Y
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MO'?@?^TIH_Q;NKWP]J=A<^#?B%I?RZGX4U;"7,)_YZ1'I-$>TBY!!&<5[%0
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M%)55&9&=R6;..!@*.*U_!'AVWA^$7[+%N))2ECKL<L9)&6/V6['S<?[1Z8H
M].\'_'*Q\2ZWJVMZ%\.KY_!5G-?6\WC6)+9%F>U\P3,D6[SI$WQ/&'"G+#CC
MFK_@WXO3_&KX'^(?$X\-W6@:5>:3-<:=+<W=O/\ :X'@9ED_<N^PCHR-AE/!
M%?.WA?XD>(?@C^UQ??!'PW?_ /% FWU#Q##:WD22RVTLT<MR\,<F 1#YS,P4
MY89(W8XK;_X)KZN?BW\)_B%XLUBTM+.7Q)KDMK>:5I4(MM/010+$7BA7[CR
MEI&!^9N>* /CO_@B<@;]H/QOD9'_  B[C'_;W;U^Q]EI5EIF_P"QV<%IYAR_
MD1*FX^IP.:\E^"W[(OPG_9Y\07VM^ /"B:!J=[:_8YYUO;B??#O5]N))& ^9
M5.0,\5[%NH =5'4M"TW63$;_ $^UOC$<QFYA638?49!Q5S=1NH 4*%    '
) [44FZB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 25, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CORCEPT THERAPEUTICS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001088856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 25,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0487658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Redwood Shores Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-3270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CORT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d123475d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cort-20260325.xsd</File>
    <File>cort-20260325_lab.xml</File>
    <File>cort-20260325_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d123475d8k.htm">d123475d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d123475d8k.htm": {
   "nsprefix": "cort",
   "nsuri": "http://www.corcept.com/20260325",
   "dts": {
    "schema": {
     "local": [
      "cort-20260325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cort-20260325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cort-20260325_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d123475d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-03-25_to_2026-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d123475d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-03-25_to_2026-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d123475d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.corcept.com//20260325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-26-123543-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-123543-xbrl.zip
M4$L#!!0    ( /EK>5P_Y%ZA.0,  $<+   1    8V]R="TR,#(V,#,R-2YX
M<V2]5FUOVS80_EZ@_^&J3QLPB7Z!BUF(4W1+ P1(L\)-BWTK:.KL$*-(C:22
M^-_O2$F.[,2>DPS+EU"\>^Z>>Z5//MR7"F[1.FGT+!EF@P10"U-(O9HEM4NY
M$U(F'T[?OCEYEZ9P=GYQ!2G<>%^YG+&[N[NL6$KMC*H]67"9,"6#-.WT?[_^
M!M\;ZSG,42%W"*/W@PG\5DM5Y*,!?8P'XVS2!UGDP1H4W&,.8S::L* (TWST
M:SX<P)?/\(D[CU;#M2RQ#S75VLK5C8>?Q,\006=&:U0*UW N-=="<@5?.[Z_
MP(46&7Q4"N8!YHBD0WN+1=9:O7=%[L0-EOSM&P#*EG:Y)I-U.4M"&MHLW"^L
MRHQ=L<);YM<5,E)*20NM%$D/^N^X1Q@J0Y"X#7#)W2*".DE(SZ2'$,;Z+3=T
M(;#RL3Q-SK?T"Y0;]<C(H<A6YI:18-=VD,NG8Q@-!F-&W> IS=B#**G_.H (
MX@4U1M_)(\C=. *&T^F41>D.I<)O1]!:G[!&&+6Y]U8N:H_GQI9GN.2U(E2M
M_ZZYDDN)1=2B+BU1^RV=;0W/[0K]%2_155S@<S)-[?146,1TR/[\?/DU=EIR
M&@  L?ED65$UH>G!2R/B:!S(9OA*NR*DX2H=CM+Q,"-C">@G2>^I(+!7$^EJ
M^R(BF\8XFHC;U\#AD(;#/N]/M_V+,[ [SB'^:8A_^/ZH^!^M@_^ B=%7KR73
MVVDOKXGF4C0KJSD>7Y<'Y*MZLUL*(0^''>]ND=9K],FU-CXZZC/A527UTK17
M=!F:..\Z>8Y+B-LKYU98H_#PCF.5-15:+VG%/PQ#8^#&XG*6A$V?=GOFA^*+
MC/9,I_+(P?9X!3$C"*K+!WH=UDL?P)=!#$%.;R57&].A'6:)H[RKWGC^S^%6
M%I\;+D$<+?=8MOU1?^EI/3OXX.>:-" <OLTO]CX/F_>!>7YOM"G7#<<S(^KP
M G7_/^KBDR9FZPMJ+%M&5@E(>DCFI/[C*/4-QXYE@?2[3<;N'0["'_VLZRST
MCUP7T)B#GKT3MFMDUW[ML/A#G\:SX$K4:I/S%MQJ' +N5NMXY .S_;CVMJM7
M-\5L=XS;F_ZX-U?-NJ'/?P!02P,$%     @ ^6MY7+C))/-?!@  O$,  !4
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MX)[-?4\?>_U=!5D8Q4<JV7^)07((:R0(I1;FDY>;>6:7-]SW#H;]E0I['TS
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M(O"+[J\!>TLY-NB?S,B0?R[9$O F#* $$X@6=NH"JE"O5P4AYLE)P;6\D?C
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MBG7)Q7)64,V$+\'6[\>N_0]02P,$%     @ ^6MY7+9? I,A'0  \8   !$
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M;;@N5Q/@0V"Z1 CTODNYKYEWN'Y0YU28ZCD4=C]#.G,,T:]D)":451DIE#L
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MP].3_?\'4$L! A0#%     @ ^6MY7#_D7J$Y P  1PL  !$
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A-61E>#DY,2YH=&U02P4&      4 !0!  0  <#L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d123475d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cort-20260325.xsd" xlink:type="simple"/>
    <context id="duration_2026-03-25_to_2026-03-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001088856</identifier>
        </entity>
        <period>
            <startDate>2026-03-25</startDate>
            <endDate>2026-03-25</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2026-03-25_to_2026-03-25"
      id="Hidden_dei_EntityRegistrantName">CORCEPT THERAPEUTICS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-234">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-03-25_to_2026-03-25"
      id="Hidden_dei_EntityCentralIndexKey">0001088856</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-245">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-246">2026-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-247">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-248">000-50679</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-249">77-0487658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-250">101 Redwood Shores Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-251">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-252">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-253">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-254">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-255">327-3270</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-256">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-257">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-258">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-259">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-260">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-261">CORT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-262">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-03-25_to_2026-03-25" id="ixv-263">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
